200 results
Keyword tofacitinib Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Zeposia
ozanimod hydrochloride, Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative
Date of authorisation: 20/05/2020,
, Revision: 4, Authorised, Last updated: 29/11/2022
-
List item
Human medicine European public assessment report (EPAR): Olumiant
baricitinib, Arthritis, Rheumatoid
Date of authorisation: 13/02/2017,
, Revision: 10, Authorised, Last updated: 29/06/2022
-
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
Secukinumab, Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Revision: 28, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Yuflyma (updated)
adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 11/02/2021,
, Revision: 9, Authorised, Last updated: 30/01/2023
-
List item
Human medicine European public assessment report (EPAR): Humira
adalimumab, Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 08/09/2003, Revision: 89, Authorised, Last updated: 16/12/2022 -
List item
Human medicine European public assessment report (EPAR): Comirnaty (updated)
Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020,, , Revision: 38, Authorised, Last updated: 03/02/2023
-
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2017
CHMP, Last updated: 27/01/2017tofacitinib) for the treatment of rheumatoid … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021
PRAC, Last updated: 12/03/2021cardiovascular events and cancer with tofacitinib as compared to tumour necrosis … trial (A3921133). Xeljanz (tofacitinib) is a medicine for treating … NAP)........................................................................................................15 4.2.3. Tofacitinib - XELJANZ (CAP) ........................................................................................15 … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023 (new)
CHMP, Last updated: 27/01/2023kinase (JAK) inhibitors INN tofacitinib, abrocitinib, baricitinib … -
List item
Human medicine European public assessment report (EPAR): Tremfya
guselkumab, Psoriasis
Date of authorisation: 10/11/2017, Revision: 8, Authorised, Last updated: 22/07/2022 -
List item
Human medicine European public assessment report (EPAR): Orencia
Abatacept, Arthritis, Psoriatic; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid
Date of authorisation: 21/05/2007, Revision: 37, Authorised, Last updated: 21/02/2022 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2019
PRAC, Last updated: 31/10/2019PRAC concluded that Xeljanz (tofacitinib) could increase the risk … -
List item
Withdrawn application: Olumiant (updated)
baricitinib, date of withdrawal: 07/12/2022, Post-authorisation, Last updated: 02/02/2023 -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013
CHMP, Last updated: 26/04/2013Xeljanz INN tofacitinib citrate Marketing-authorisation … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022
PRAC, Last updated: 28/10/2022the JAK inhibitor Xeljanz (tofacitinib) and preliminary findings … filgotinib - JYSELECA (CAP); tofacitinib - XELJANZ (CAP); upadacitinib … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022
PRAC, Last updated: 11/02/2022the JAK inhibitor Xeljanz (tofacitinib). The results showed that … filgotinib - JYSELECA (CAP); tofacitinib - XELJANZ (CAP); upadacitinib … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
PRAC, Last updated: 17/05/2019a new review of Xeljanz (tofacitinib) and has recommended, as … -
List item
National expert: Loreto Carmona, European Medicines Agency (updated)
- Declaration of interests - 81.42 KB | PDF
- Curriculum Vitae - 108.52 KB | PDF
-
List item
Withdrawn application: Plivensia
date of withdrawal: 26/10/2017, Initial authorisation, Last updated: 10/11/2017 -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018
CHMP, Last updated: 27/04/2018Name of medicine Xeljanz INN tofacitinib Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013
CHMP, Last updated: 26/07/2013Xeljanz INN tofacitinib Marketing-authorisation applicant … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021
CHMP, Last updated: 25/06/2021Xeljanz INN tofacitinib Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021
CHMP, Last updated: 15/10/2021Xeljanz INN tofacitinib Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018
CHMP, Last updated: 01/06/2018Name of medicine Xeljanz INN tofacitinib Marketing-authorisation holder … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021
PRAC, Last updated: 11/06/2021recommendations for use of Xeljanz (tofacitinib). Final results from a recently …